Showing results (1731-1740 of 1,909) with videos related to
Sort By:
Pageof 191
Archives of Disease in Childhood|August 22, 2020
Height of fever and invasive bacterial infectionKenneth A Michelson, Mark I Neuman, Christopher M Pruitt, et al.Circulation|February 8, 2006
Renal function as a predictor of outcome in a broad spectrum of patients with heart failureHans L Hillege, Dorothea Nitsch, Marc A Pfeffer, et al.American Heart Journal|March 30, 2013
The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical developmentAdel Nada, Gary A Gintant, Robert Kleiman, et al.Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.European Journal of Heart Failure|June 1, 2005
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEileen O'Meara, Eldrin Lewis, Chris Granger, et al.Journal of Thrombosis and Thrombolysis|July 20, 2020
Biomarkers of platelet activation and cardiovascular risk in the DAPT trialDavid D Berg, Robert W Yeh, Laura Mauri, et al.Pain Reports|October 30, 2023
A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathyDavid Michelson, William W Chin, Robert H Dworkin, et al.European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.European Journal of Heart Failure|April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programmeNathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.Haematologica|November 9, 2014
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemiaJeffrey E Lancet, Gail J Roboz, Larry D Cripe, et al.Pageof 191